The CAPN2 antibody is a crucial tool in studying calpain 2. a calcium-dependent cysteine protease belonging to the calpain family. Calpain 2. encoded by the *CAPN2* gene, forms a heterodimer with the regulatory subunit CAPNS1 and plays a key role in cellular processes such as signal transduction, apoptosis, cytoskeletal remodeling, and cell migration. Unlike its isoform calpain 1 (CAPN1), which requires micromolar calcium concentrations for activation, calpain 2 is activated at millimolar levels, often functioning in pathophysiological contexts. CAPN2 dysregulation has been implicated in diseases including cancer, neurodegenerative disorders, and muscular dystrophy. The CAPN2 antibody enables researchers to detect and quantify calpain 2 expression, assess its localization via immunohistochemistry or immunofluorescence, and investigate post-translational modifications or cleavage events in diverse biological samples. It is widely used to explore calpain 2's role in disease mechanisms, substrate specificity, and interaction with regulatory proteins like calpastatin. Validation of CAPN2 antibodies is critical, as cross-reactivity with other calpain isoforms or degraded fragments can complicate interpretations. Ongoing research leverages these antibodies to develop targeted therapies modulating calpain 2 activity, particularly in conditions linked to excessive proteolysis or calcium imbalance.